News

The Dose Podcast- Episode 4 "PAN-TB and Novel Regimen Development"

 

Episode 4 of the WGND's podcast series, The Dose, is now available for streaming. In this episode join our moderator, Shobha Shukla, as she speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development. The PAN-TB collaboration of philanthropic, non-profit, and private sector organizations supported by the Bill & Melinda Gates Foundation strives to accelerate the development of shorter, safer, and affordable TB therapy with minimal existing drug resistance. 

The Working Group on New TB Drugs (WGND)’s podcast series The Dose explores pressing issues and emerging solutions related to research and development of new tuberculosis drugs. The podcast series provides the opportunity to hear from key experts in the TB drug field and disseminate information using a new and innovative platform. The WGND strives to cover the most pressing issues facing TB drug development and the podcast series has the potential to reach a broad audience. The WGND hopes to use the podcast platform to bring together drug developers, researchers in the TB R&D field, TB patients, and donors to discuss, prioritize, and develop strategies to help meet the most pressing drug research and development needs related to tuberculosis.

Episode 4 "PAN-TB and TB Regimen Development" 

Moderator:
Shobha Shukla
Citizen News Service
India

PAN-TB Leader
Debra Hanna
Senior Program Officer, TB Drugs, BMGF
USA

PAN-TB Partner
Robert Bates
Director, Head of Tuberculosis Discovery, GSK
Spain

To listen, click play on the vimeo box at the top of the page or visit https://vimeo.com/534117379. The views expressed in this podcast are those of the individual panelists and do not necessarily represent their organizations’ opinions.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...